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Introduction 
 
Hypertensive disorders in pregnancy represent a great dilemma for the clinicians. The 
incidence and the complications, both for mother and fetus, are high and occasionally 
severe.  
Preeclampsia (PE) is the leading cause to perinatal mortality and morbidity1. Affecting 
the outcome of 2-8% of pregnancies, along with the other hypertensive disorders of 
pregnancy, it is a major contributor to maternal mortality everywhere2.  Maternal death 
caused by hypertensive disorders represents 26% of the total in Latin America and the 
Caribbean, 9% in Africa and Asia3. The incidence in USA and Europe has risen maybe 
for the increased incidence of risk factors: chronic hypertension, obesity and diabetes4. 
Other hypertensive disorders in pregnancy are pre-existing hypertension and gestational 
hypertension. In the reproductive years, chronic hypertension is a rare disease, while 
gestational hypertension and preeclampsia constitute the bulk of hypertensive disorders 
in pregnancy. 
These pregnancy complications not only alter the immediate outcomes of pregnancy at 
the time of delivery, but also the long-term cardiovascular health of the affected women 
and children. For example, a history of preeclampsia increases a female’s risk of 
myocardial infarction, stroke or diabetes mellitus by two to eight folds over the next 
two decades5. Furthermore, such women have also been shown to have increased risk 
for renal diseases, such as, focal segmental glomerulosclerosis and microalbuminuria6.  
Moreover, newborns born after a pregnancy complicated by preeclampsia have a two to 
eightfold increased risk for hypertension, cardiovascular disease, diabetes mellitus or 
renal disease as adults7. The pathogenesis is unclear: maybe these conditions are related 
to epigenetic modification, postnatal growth acceleration, permanent alteration caused 
by fetal malnutrition8. 
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Hypertensive disorders in pregnancy 
Pregnancy induced hypertensive disease is a multisystem disorder of uncertain cause 
that is specific of human pregnancy. It is a newly onset hypertension in previously 
normotensive women coupled with or without elevated urine protein, developed after 20 
weeks of gestation, as defined by the International Society for the Study of 
Hypertension in Pregnancy (ISSHP)9,10.  
Hypertension is defined as a blood pressure of at least 140 mm Hg (systolic) or at least 
90 mm Hg (diastolic) on at least two occasions and at least 4–6 h apart after the 20th 
week of gestation in women known to be normotensive beforehand11. Hypertension is 
regarded as severe if there are sustained rises in blood pressure to at least 160 mm Hg 
(systolic), at least 110 mm Hg (diastolic), or both12. Proteinuria is defined as excretion 
of 300 mg or more of protein every 24 h. If 24-h urine samples are not available, 
proteinuria is defined as a protein concentration of 300 mg/L or more (>1 + on dipstick) 
in at least two random urine samples taken at least 4–6 h apart11. 
Syndrome can be exacerbated to severe hypertension and proteinuria (“severe 
preeclampsia”) that may lead to eclampsia, an obstetric emergency associated with 
brain convulsions, cerebral oedema and stroke, a life threatening condition for the 
mother and her baby13. HELLP (haemolysis, elevated liver enzymes, low platelets) 
syndrome may correlate to severe preeclampsia and is characterized by elevated liver 
enzyme activities and reduced numbers of platelets indicating injury to the liver, blood 
system and potentially other organs. The HELLP syndrome occurs primarily in white, 
multiparous women above the age of 25 years14.  
According to the National Institute of Child Health and Human Development 
(NICHD) 15 , confirmed by large scale studies of the Maternal-Fetal Medicine 
Foundation 16  and other international surveys 17 , preeclamptic patients deliver 
prematurely (25% between 34-37 weeks of gestation and 10% before 34 weeks). The 
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more premature is the delivery, the more severe are the complications for both mother 
and child. The frequency of eclampsia, stroke, cerebral vascular accident and other 
severe complications is higher in preterm preeclampsia compared to term preeclampsia. 
More than 75% of babies born from early preeclampsia (<34 weeks) and over 50% of 
those born preterm (34–37 weeks) are either small for gestational age (SGA) or show 
intrauterine growth restriction (IUGR): these newborn account for the major fraction of 
intra-partum and post-partum death, cerebral palsy, blindness and motor and cognitive 
disorders. These complications are less severe in term preeclampsia18 19 20. 
We point out the two different aspects for this pathology: one involving the mother, and 
the other involving fetus. Pathogenesis and aetiology are still unclear.  
 
Pathogenesis of pregnancy induced hypertensive disorders 
It is well known that preeclampsia is associated with poor placentation and incomplete 
remodelling of the uteroplacental spiral arteries21. In this condition uterine spiral arteries 
fail to undergo the normal thinning out of muscular walls that permits enhanced 
perfusion of the placenta22. Thus, perfusion of the intervillous space is impaired, leading 
to placental hypoxia23 24.  However the association is not specific. Poor placentation 
may occur with IUGR without features of preeclampsia25 or with partial features such as 
pregnancy-induced hypertension. Poor placentation would be expected to cause IUGR. 
However IUGR is not a consistent feature of hypertensive disorders (HD) being 
confined largely to the early onset syndrome. In hypertensive disorders, at or beyond 
term, neonates are not growth restricted and may even be large for dates26. 
We consider a heterogeneous syndrome resulting by many factors.  
To understand the pathophysiology of hypertensive disorders we have to consider the 
normal low grade systemic (vascular) inflammation response of the physiological 
pregnancy27. Pregnancy causes an intravascular inflammation that lead to endothelial 
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dysfunction: endothelial cells produce pro-inflammatory cytokines stimulating 
leukocytes, platelets and other humoral components28. Oxidative stress is both a cause 
and consequence of inflammation29. From the beginning of the pregnancy we note a 
maternal augmentation of pro-inflammatory index: leucocytosis30, increasing IL-6 and 
TNF-α plasma concentration31, fibrinogen32, PAI-133. Systemic inflammation induces 
also other metabolic adaptation to the pregnancy: in particular an insulin resistance and 
hyperlipidaemia develop in the second trimester34 35.  
This inflammation response is exacerbated in hypertensive diseases 35.  
But it’s important to consider many other predisposing factors to hypertensive 
disorders. Poor placentation is a separate disorder that typically leads to the maternal 
syndrome, depending on the degree to which it produces inflammatory signals. This 
inflammatory response may depend on fetal genotype and also on the maternal response 
to those signals, which depend on maternal genotype36. Many other pathophysiologic 
abnormalities have been suggested to explain mechanisms leading to the development 
of preeclampsia: immunologic intolerance between feto-placental and maternal tissues, 
placental and endothelial dysfunction, immune maladaptation to paternal antigens, 
exaggerated systemic inflammatory response, maladaptation to the cardiovascular or 
inflammatory changes of pregnancy, dietary deficiencies, and genetic abnormalities37. 
The opinion was that the clinical findings of hypertensive disorders could manifest as 
either a maternal syndrome (hypertension and proteinuria with or without other 
multisystem abnormalities) or fetal syndrome (fetal growth restriction, reduced amniotic 
fluid, and abnormal oxygenation)38 39.  
Many different classifications were used to describe hypertensive disorders 40 41: mild, 
moderate, and severe, as well as early and late. The concept of early and late 
hypertensive diseases is more modern, and it is widely accepted that these two entities 
have different aetiologies and should be regarded as different forms of the probelm41. 
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Early-onset form (before 34 weeks) is commonly associated with abnormal uterine 
artery Doppler, fetal growth restriction, evidence of ischemic lesions on placental 
examination and adverse maternal and neonatal outcomes42 43. In contrast, late-onset 
hypertensive disorder (after 34 weeks) is mostly associated with normal or slightly 
increased uterine resistance index, a low rate of fetal involvement, and more favourable 
perinatal outcomes43 44. Recently some Authors demonstrated that early-form and 
IUGR fetus could have the same origin, placenta mediated disease45 46: placental growth 
factor (PIGF), could be a useful second-trimester screening test for an early form of the 
disease, but not for late-onset preeclampsia/IUGR. 
For this reason, two broad types of preeclampsia have been suggested: placental and 
maternal43 preeclampsia.  
It is generally agreed that poor placentation is strongly associated with IUGR, even in 
the absence of hypertension/preeclampsia, but it is less clearly documented in 
association with hypertension/preeclampsia and normal fetal growth. Thus, when Ness 
and Roberts pointed out that 70% of infants of preeclamptic women do not show IUGR, 
this suggested that abnormal placentation is not likely to be associated with the majority 
of cases of preeclampsia43. It later emerged that IUGR is a feature of early, not term, 
disease47, suggesting that poor placentation is more likely to underlie this presentation. 
Most hypertensive disorders occurs at term, that is, after 37 weeks’ gestation48. 
Although term preeclampsia is less often associated with placental dysfunction, severe 
maternal complications can still occur. For example, 20% of cases with HELLP 
syndrome49 and 55% of cases with eclampsia49 occur at term. In other words, term 
hypertensive disorder is not benign just because the fetus is less threatened by IUGR, 
such as in early-onset preeclampsia. 
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Placental and maternal preeclampsia 
Redman50 wrote an article about the different kind of inflammation in preeclampsia and 
he suggested that the disease constitutes a spectrum that includes so-called ‘maternal’ 
and ‘placental’ preeclampsia.  
This new concept retains there are two different pathogenesis of preeclampsia. The 
placental form is related to a placentation defect at the beginning of the pregnancy. The 
strongest hypothesis is that there is an inadequate placental invasion of the 
myometrium51. The throphoblast invasion is inhibited, the arteries are poorly remodeled 
and the capacity of the uteroplacental circulation is too small52. This condition leads to 
an oxidative stress with tissue damage and the release of placental factors, the first step 
for endothelial dysfunction and tissue inflammation53. All inflammatory networks are 
involved (leukocytes, platelet, endothelium, clotting cascade…) maybe enhanced by 
throphoblast debris into maternal circulation (syncytiotrophoblast microparticles, RNA-
DNA of fetal origin, cytotrophoblast cells). Probably the increased release of 
trophoblastic debris is caused by apoptotic process and necrosis related to placental 
damage54 
Maternal form is not necessarily associated with abnormal placentation and inadequate 
perfusion. There is a pre-existing endothelial and vascular dysfunction, in particular in 
women with risk factors: obesity, diabetes, metabolic syndrome are conditions that 
predispose the subject to develop the syndrome. Indeed adipose tissue is a very active 
endocrine organ28: Adipocytes produce and release numerous biologically active 
substances, such as leptin, adiponectin, interleukins (IL)-1, IL-6, IL-8, IL-10, tumor 
necrosis factor (TNF), interferon-γ and monocyte chemo-attractant protein (MCP)-1, 
collectively termed adipokines55. This low-grade inflammation might explain the higher 
prevalence of preeclampsia in obese population. Pregnancy may constitute a metabolic 
and vascular stress test52, which reveals a woman’s health in later life and which is 
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consistent with the higher incidence of ischemic heart disease, stroke, and hypertension 
that becomes evident many years after an episode of preeclampsia56. 
In summary, we can consider placental preeclampsia as an abnormal placenta in a 
normal woman, and the maternal preeclampsia as a normal placenta within a woman 
who suffers from a pre-existing problem, such as obesity, metabolic syndrome or 
diabetes.  
The pregnancy become a systemic inflammatory stress for women, particularly during 
the second half of gestation, to which both endocrine and placental factors contribute.  
Placental preeclampsia is caused by an inadequate trophoblastic invasion of the 
maternal spiral arteries, that cause first a local inflammatory process and later a 
systemic inflammation, which has been documented by altered Doppler ultrasound of 
uterine arteries and often associated with a higher incidence of fetal growth restriction.  
Conversely, maternal preeclampsia is associated with normal placentation and fetal 
growth and is thought to be a manifestation of an underlying metabolic disorder with 
chronic inflammatory state. 
Further data support the hypothesis of two different causes leading to preeclampsia: 
pregnancy is characterized by certain structural and functional changes in the maternal 
cardiovascular systems. Adequate cardiovascular adaptation during early pregnancy 
leads to a state of high blood flow and low vascular resistance, which is a prerequisite to 
successful pregnancy outcome. In contrast, inadequate or excessive cardiovascular 
adaptation before 20 weeks of gestation is associated with pregnancies complicated by 
gestational hypertension, preeclampsia, IUGR or a combination of these57. 
In 2008, Valensise58 observed two different groups of women that subsequently develop 
early or late preeclampsia. Patients with early onset preeclampsia had significantly 
higher rates of advanced maternal age, bilateral uterine arteries notching, lower 
gestational age at delivery and lower neonatal weight compared to both control and late 
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preeclampsia groups. In contrast, patients with late onset preeclampsia had higher body 
mass index compared to the other two groups. 
Moreover he proposed that early and late onset preeclampsia develop from two distinct 
hemodynamic states: patients with early preeclampsia had significantly high total 
vascular resistance and lower cardiac output compared to those with late preeclampsia 
that present low vascular resistance and high cardiac output. 
Valensise concludes that early preeclampsia appears to be more related to the evolution 
of an extremely altered cardiovascular response probably triggered by a placental 
disorder; instead, late preeclampsia seems to be more linked to maternal constitutional 
factors. 
 
Prevention of preeclampsia: uterine artery Doppler velocimetry in first trimester 
The primary prevention of any preeclampsia remains a considerable challenge in 
obstetrics. Although the symptoms of preeclampsia generally manifest themselves in 
the second to third trimester of pregnancy, their underlying pathology takes place in the 
first trimester51. 
Many researchers and physicians are still working to identify clinical elements in the 
first trimester to evaluate the effective risk of a woman to develop the disease, in order 
to allow targeted prenatal surveillance. Early prediction of preeclampsia would allow 
the development of treatments that could reduce the incidence of complications 
originating from this disease. Screening is valuable only if there is a therapeutic 
intervention that can improve the outcome. For this reason the efforts of the scientific 
community were concentrated on first trimester of pregnancy: indeed this is the best 
moment to modify the natural history of the pathology. This was definitely proved by 
usage of low-dose aspirin: in particular, it has been observed that the assumption of 
low-dose aspirin after the 16th week in patients with risk factors slightly reduces the 
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incidence of early preeclampsia59. When used before the 16th week, the relative risk for 
preeclampsia is sensibly reduced60.  
The most recent meta-analysis that has been published further demonstrates that low-
dose aspirin started before16 weeks’ gestation was particularly effective in preventing 
preterm preeclampsia rather than term preeclampsia (RR: 0.11, 95% CI: 0.04–0.33 
versus RR: 0.98, 95% CI: 0.42–2.33)61. Successful implementation of this intervention 
is therefore dependent on being able to screen effectively in early pregnancy. For this 
reason current clinical risk assessment for preeclampsia is done in the first trimester62 
for early identification of women who can benefit of preventative treatment such 
aspirin63. This includes women with at least one high risk factor (previous history of 
hypertension in pregnancy, chronic kidney disease, autoimmune disease, type 1 and 2 
diabetes and chronic hypertension) or two moderate risk factors (first pregnancy, aged 
40 years or more, pregnancy interval of more than 10 years, Body Mass Index BMI of 
35 or more, family history of preeclampsia, multiple pregnancy). 
The traditional approach was based on maternal history and systematic use of systemic 
mean arterial pressure (MAP) 64 . Thus, for women considered at high risk for 
preeclampsia, due to previous preeclampsia or chronic hypertension or diabetes or 
multi-fetal pregnancy, the frequency of those who will develop preeclampsia is 19% 
(previous preeclampsia), 22% (diabetes) and 25% (chronic hypertension)65. Although 
the screening by maternal history alone will detect only 30% of women who will 
develop preeclampsia, the clinical risk-based strategy is not effective for nulliparous 
women without other risk factors66. 
Many other biophysical and biochemical parameters were introduced for the early 
identification of preeclampsia. In particular uterine artery Doppler pulsatility index 
(UtA-PI) was studied during second trimester67, and serum placental markers68. These 
methods alone do not achieve detection rates sufficient to be used as screening test.  
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A great innovation in obstetrics was brought by the introduction of the uterine arteries 
Doppler velocimetry in clinical practice. Uterine arteries analysis gives useful 
information on placentation: this non-invasive exam provides information on the 
otherwise unknown placental tissue, the maternal-placental vascularization state, and 
further additional deviations from physiology towards pathology. The evaluation of 
uterine arteries in the first trimester may unveil the secrets of early placental 
development. Many studies were based on the predictive value of uterine arteries for 
preeclampsia in the first trimester69 70. There is a stronger association between UtA-PI 
and early-preeclampsia, with respect to late-onset preeclampsia, probably for the 
different aetiology of the disease. Indeed we could consider uterine arteries as a mirror 
of placental function and development.  
A recent meta-analysis71 of 55,974 women, observed that the predictive capacity of 
uterine arteries to detect early-preeclampsia in a low risk population has the same 
performance as clinical high risk factors. This makes a strong case for introducing 
uterine artery Doppler assessment in the first trimester and to develop a prediction 
model incorporating the clinical characteristics with uterine artery Doppler to increase 
the accuracy of risk assessment64.  
Since fetal growth is a multifactorial process in which placentation is only one of the 
factors involved, the use of a single parameter such as Doppler velocimetry remote from 
the delivery to predict birth weight in a low-risk population seems to be useless72. Fetal 
growth restriction is caused by multiple aetiologies including aneuploidy, genetic 
syndromes, environmental factors, drug abuse, smoke, intrauterine infections, maternal 
thrombophilia. The prediction of the pathophysiologic process through the uterine 
arteries in the first trimester seems to be poor. Uterine arteries predict better early 
IUGR, because of its strong association with preeclampsia73. 
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In order to improve the prediction of the disease, many authors have combined the 
patient history with a series of biophysical and biochemical markers that change from as 
early as the first trimester of pregnancy in cases that subsequently develop preeclampsia 
or IUGR. Studied biophysical markers include mean arterial blood pressure74, uterine 
artery Doppler75 and more complex evaluations such as maternal cardiac output76 and 
brain hemodynamic measurements77. Several biochemical markers have been tested for 
the prediction of preeclampsia and IUGR, including products of fetal and placental 
origin, markers of renal or endothelial damage, angiogenic and antiangiogenic factors, 
and markers of oxidative stress as reviewed by Giguère in 201178. Maternal serum 
markers, such as inhibin A, activin A, soluble fms-like tyrosine kinase 1 (sFlt-1) and 
soluble endoglin, when used alone are proved poor predictors of preeclampsia79 80.  
 
Aim of the study 
 
Pregnancy induced hypertension is a complex and heterogeneous spectrum of 
pathologies that involves 5-10% of pregnancies. It is one of the major contributors to 
maternal and perinatal mortality and morbidity worldwide. 
Until now the classification of these diseases was based on timing of insurgence or 
delivery, or clinical manifestation using the grade of the pathology. 
The aetiology of this syndrome was not considered. 
In the last years, many Authors focused their attention on the heterogeneity of this 
group of disease, underline the different origin between the placental and maternal 
preeclampsia. The first one is associated with fetal growth restriction, alteration of 
placenta and fetal Doppler velocimetry and important maternal involvement, thought to 
be a consequence of impaired placentation. This condition leads to an oxidative stress 
with tissue damage and the release of placental factors, the first step for endothelial 
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dysfunction and tissue inflammation with possible consequence on fetal growth. The 
second one is associated with normal fetus-placental blood flow and rarely with 
important clinical involvement for the mother. The underlying pathophysiological 
process to this conditions thought to be the metabolic syndrome with chronic low-grade 
inflammation and increased insulin resistance characterizing typically women with 
android obesity. This is the rationale to support the theory that stress mainly the 
aetiology of the disease, and that considers preeclampsia of placental origin associated 
with IUGR, while preeclampsia of maternal origin associated with appropriately growth 
fetus (AGA). 
Despite improvement in the understanding of the pathophysiology of these conditions, 
ability to accurately predict pregnant woman who will develop preeclampsia is limited. 
This greatly impairs the development and testing of preventive interventions.  
All screening tests using to early detection of women at high risk of this pathology 
considered the classification of hypertensive disease in early-onset HD and late-onset 
HD. This is a rigid and strained classification that not considered the various possibility 
of a complex syndrome independently from gestational age. 
We want to consider the aetiology of the pathologies, through an accurate definition and 
study of symptoms and signs of the disease.  
The aim of the study is to evaluate a new classification of hypertensive disease based on 
physiopathology, and not on temporary factors. We want to study uterine arteries 
diagnostic power on first trimester to predict hypertensive disorders. 
 
 
 
 
 
	   16	  
Material and Methods. 
 
This is a prospective longitudinal cohort study of pregnant women followed in two 
hospital: Prenatal Diagnosis and Gynaecologic Unit of the Institute for Maternal and 
Child Health – IRCCS “Burlo Garofolo” in Trieste and Obstetrics and Gynaecologic 
Unit of Children’s Hospital – ICP “Vittore Buzzi” in Milan, Italy.  
The study was approved by Ethics Committee of the Institute for Maternal and Chid 
Health – IRCCS Burlo Garofolo and of the Istituti Clinici di Perfezionamento (ICP)- 
Buzzi Children’s Hospital. 
This study was offered to pregnant women at the time of first trimester ultrasound 
aneuploidy screening. All women were recruited consecutively from October 2007 to 
April 2009 in Triest and from October 2009 to December 2012 in Milan. 
We enrolled singleton pregnancies between 11+0 and 13+6 weeks of gestation.  
All pregnancies were dates by last menstrual period if consistent with crown-rump 
length measurements (± 7 days), or by CRL measurements if it was not consistent with 
menstrual dating.  
The inclusion criteria were: 
• single pregnancy; 
• absence of fetal anomalies; 
• age major to 18; 
• obtained informed consent; 
The exclusion criteria were: 
• multiple pregnancy; 
• presence of fetal anomalies (fetal malformation, aneuploidy, congenital syndrome); 
• miscarriage before 20 weeks; 
• termination of pregnancy (TOP); 
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• intrauterine fetal-death; 
• age inferior to 18; 
• informed consent not obtained. 
 
During the first visit a written informed consent was collected. At the time of inclusion, 
women had an interview with a researcher and answered a standardized questionnaire 
on maternal characteristics and medical history. Demographic and clinical data 
included: age, racial origin (Caucasian, African, Asian, East Asian and Mixed), 
smoking habit, family history of hypertension, medical pathologies, drug assumption, 
parity (nulliparous if no delivery beyond 20 weeks), method of conception (spontaneous 
or IVF), obstetrical history.  
The maternal weight and height were measured and the body mass index (BMI) was 
calculated. 
We performed ultrasound examinations measuring fetal CRL, Nuchal Translucency 
(NT) and Nasal Bone (NB). During the ultrasound exam, Doppler velocimetry of 
uterine arteries (left and right) was performed. All indices were recorded: Pulsatility 
Index (PI) and Resistant Index (RI). For the purposes of this study the mean value of the 
pulsatility index from the left and right uterine artery was used (Mean UtA PI)81. 
Maternal serum PAPP-A and free β Human Chorionic Gonadotropin (β-hCG) were 
determined to calculate the combined patient-specific risk for trisomy 18 and 2182 83. 
All participating sonographers are certified by the Fetal Medicine Foundation for first 
trimester screening. The ultrasound scan was performed using a high-resolution, real-
time ultrasound equipment (Voluson E8 and Voluson 730 Expert, General Electric 
Medical Systems, Milwaukee, WI, USA) equipped with a 5-MHz to 7.5-MHz 
curvilinear transabdominal probe.  
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Uterine arteries Doppler velocimetry assessment 
Both uterine arteries were examined as suggested by the Fetal Medicine Foundation, 
London, UK (www.fetalmedicine.com/fmf) by an operator certified by the Fetal 
Medicine Foundation for the first trimester screening. A sagittal section of the uterus 
was obtained and the cervical canal and internal cervical os identified. The transducer 
was tilted from side to side and color flow mapping was used to identify each uterine 
artery along the side of the cervix and uterus at the level of the internal os. Pulsed wave 
Doppler was used with the sampling gate set at 2 mm to cover the whole vessel and 
with care taken to ensure that the angle of insonation was less than 30°. When three 
similar consecutive waveforms were obtained, the UtA-PI and UtA-RI were measured 
and the mean UtA-PI was determined. The first trimester Doppler results were not 
shown in the ultrasound report but the mean PI was used for analysis. The presence or 
absence of an early diastolic notch was not included in the analysis84. 
 
Laboratory technique 
Once the ultrasound examination was performed and the gestational age confirmed, a 
blood sample (5 cc) was taken from each woman. 
Maternal serum PAPP-A was measured using a kit for B.R.A.H.M.S KRYPTOR 
automated immunofluorescent assays (Hennigsdorf, Germany; www.kryptor.net) in 
Milan and DELFIA Xpress (Perkin Elmer Life and Analytical Sciences, Turku, Finland) 
in Triest. PAPP-A and β-hCG values were converted in multiple of the median (MoM), 
which were corrected for CRL and body mass index (BMI). The samples were analysed 
by an examiner blinded to the clinical outcomes. 
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Outcome data collection 
Pregnancy outcome data were collected as follows: fetal and maternal outcomes were 
obtained either directly from the clinical record if the delivery occurred in “Vittore 
Buzzi” Hospital or in “Burlo Garofolo” hospital or by a telephone questionnaires to the 
women after delivery. 
 
Definition of outcomes 
Adverse pregnancy outcome was defined as the presence of one or more of the 
following: 
 
• Pregnancy induced hypertension (PIH):  
- Gestational hypertension (GH) was defined as diastolic blood pressure above 90 mm 
Hg or more on at least two occasions, at 4 hours apart, developing after 20 weeks of 
gestation in previously normotensive women in the absence of significant proteinuria85. 
- Preeclampsia (PE) was defined as diastolic BP of at least 110 mmHg on one occasion 
or diastolic BP of at least 90 mmHg on two consecutive occasions more than four hours 
apart, in combination with proteinuria (≥300 mg total protein in a 24-hour urine 
collection or, if this was not available, ≥ +2 proteinuria by dipstick analysis on two 
consecutive occasions at least four hours apart) developing after 20 weeks of gestation 
in previously normotensive women85.  
For the purpose of the analysis we decided to introduce a new classification of 
hypertensive disorders (HD) according with recent literature: HD of placental or 
maternal origin.  
Placental-hypertensive disorder (placental-HD) is characterized by PIH and impaired 
fetal growth, defined as fetus with ultrasound abdominal circumference below the10th 
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centile or a drop in abdominal circumference > 40th centiles in two consecutive 
ultrasound examinations.  
Maternal-hypertensive disorder (maternal-HD) is characterized by PIH with a fetus 
appropriate for gestational age, independently of gestational age at diagnosis. 
In a second time we considered also standard classification of HD based on time of 
delivery:  
- Early onset-HD (PIH and age at delivery before 34 week of gestation). 
- Late onset-HD (PIH and age at delivery after 34 week of gestation)86. 
 
• Chronic hypertension (CH) was defined as diastolic blood pressure above 90 mm Hg or 
more on at least two occasions, at 4 hours apart, developing before pregnancy or before 
20 weeks of gestation85. 
 
• Intra-uterine growth restriction (IUGR) was defined as ultrasound abdominal 
circumference below the 10th percentile according to standards references based on 
gestational age. Other causes of IUGR such as infection, anomalies and abnormal 
chromosomes were excluded in all cases87. 
 
In a preliminary study we considered as outcome also: 
• Gestational diabetes: positive 75 gr oral glucose tolerance test during pregnancy 
• Spontaneous preterm labour: delivery of a live baby before 37 weeks of gestation. 
• Large for gestational age fetuses (LGA): a birth weight over the 90th percentile 
according to standards references for weight based on gestational age87. 
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Statistical analysis 
We started with a descriptive analysis of gestational outcome, separating the unaffected 
group from the groups of women affected by PHI, CH, SGA fetus, LGA fetus, GDM, 
PTL. In a preliminary analysis we considered women with preterm labour, diabetes and 
fetus LGA, but we noted that there were no difference from control group.  
So we decided to consider women with preterm labour, gestational diabetes and LGA 
fetuses in the control group creating 4 case groups to the definitive analysis. 
We used two different classifications for the outcome. The first one considered 
hypertensive disorders in placental and maternal. The second one considered 
hypertensive disorders on time of delivery (early and late).  
We compared demographic characteristics (maternal age, BMI, ethnicity, parity, 
conception, gestational age at delivery, infant birth-weight), uterine mean PI values, 
PAPP-A and β-hCG levels among groups, for every classification.  
Data were expressed as mean ± 95% CI for continuous variables and as number and 
percentage for categorical variables. The distribution of data was evaluated with 
Kruskall-Wallis test. The results are represented as mean value and standard deviation 
(SD). Logarithmic transformation was performed to normalize mean UtA-PI. Logistic 
regression models were computed to evaluate the significance of the variables 
considered. The following variables were included: UtA mean PI, BMI, gestational age 
at time of recruitment and maternal age. The receiver operating curves (ROC) 
constructed on regression models were computed and area under the ROC (AUC) 
calculated to evaluate the performance of the model. We evaluated the 1st trimester 
model to identify: firstly, women at risk of developing placental or maternogenic HD, 
and, secondly, the early and late-onset HD. Each disease was evaluated against the 
whole cohort. The area under the curves was calculated and compared with the roctab 
and roccomp function in STATA. The test characteristics at 5% and 10% fixed false 
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positive rate were calculated with the roctab function and the estat classification 
function at the cut-off value at the 95th and 90th percentile for negative outcome. 
The analysis was performed with the program Stata/IC 11.2 for Windows (Stata Corp 
LP, College Station, USA). 
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Results 
 
4218 pregnant women were recruited in occasion of their ultrasound first trimester 
screening. At the moment of the analysis 712 patients were lost to follow up or 
excluded because incomplete data acquisition. This resulted in the cohort of 3506 
women with complete outcome follow-up, of which 18 women had first/second 
trimester miscarriage, 10 women performed a termination of pregnancy and 6 women 
had intrauterine fetal death. These patients were excluded from analysis.  
Among 3472 pregnancies included in the study, 122 women (3,5%) developed some 
hypertensive gestational disease, 56 fetuses were IUGR (1,6%), 10 women had 
chronic hypertension (0.3%) and 3284 women were unaffected (94.6%).   
If we considered PIH classification based on the aetiology, 16 women (0.5%) 
developed placental HD, 106 (3.0%) presented maternal HD. 
Table 1 reports maternal and fetal outcomes occurred in the study groups using 
classification of placental- and maternal- HD.  
  
 
 
 
 
           Table 1 
 
 
 
If we considered classification based on time of delivery, 11 women (0.3%) developed 
early-HD, 111 women (3.2%) presented late-HD. 
OUTCOME  
 
3472 
PLACENTAL HD (GH/PE + IUGR) 16 (0.5%) 
MATERNAL HD (GH/PE + AGA) 106 (3.0%) 
CH 10 (0.3%) 
IUGR 56 (1.6%) 
UNEFFECTED 3284 (94.6%) 
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In Table 2 we report the same data using classical classification of HD: early- and late-
onset HD.  
 
 
 
 
  
  Table 2 
 
 PLACENTAL HD (GH/PE + IUGR) 
MATERNAL HD  
(GH/PE + AGA)  
EARLY HD (< 34 WS) 9 2 11 
LATE HD (> 34 WS) 7 104 111 
 16 106  
          Table 3 
 
 
 
 
 
 
 
 
 
 
 
 
OUTCOME  3472 
EARLY HD (< 34 WS) 11 (0.3%) 
LATE HD (> 34 WS) 111 (3.2%) 
CH 10 (0.3%) 
IUGR 56 (1.6%) 
UNEFFECTED 3284 (94.6%) 
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Demographic variables into groups 
 
Table 4 shows the main features of case group, placental HD, maternal HD, CH group 
and SGA group.  	  
Variable Unaffected (n=3284) 
Plac HD 
(n=16) 
Mat HD 
(n=106) 
CH 
(n=10) 
IUGR 
(n=56) 
Age, years, 
mean 
(95%CI) 
32.6 
(32.4-32.7) 
31.8  
(29.2-34.4) 
33.2  
(32.4-34.0) 
34.8  
(31.3-38.4) 
31.7  
 (30.5-
33.0) 
BMI, Kg/m2, 
mean 
(95%CI)  
22.3 
(22.2-22.4)  
24.2* 
(22.1-26.2)  
24.7** 
(23.8-26.2)  
30.4** 
(26.1-34.8) 
21.6  
(20.8-
22.5)  
Ethnicity: 
Caucasian, % 96.0 93.8 95.3 100.0 94.6 
Parity : 
nulliparous, 
% 
60.6 71.4 69.6 70.0 63.6 
Conception: 
spontaneous, 
% 
97.0 100.0 91.9 80.0 100.0 
Gestational 
age at 
delivery, 
weeks 
(95%CI) 
39.5  
(39.5-39.6) 
33.0** 
(31.0-35.0) 
38.7** 
(38.3-39.1) 
39.6 
(38.7-40.5) 
38.7** 
(38.2-
39.1) 
Infant birth 
weight, gr, 
mean 
(95%CI) 
3351 
(3335-3367) 
1589** 
(1262-
1916) 
3104** 
(2986-3223) 
3359 
(3094-3623) 
2487** 
(2397-
2576) 
* for p<0.05; ** for p<0.01: comparison with group of unaffected with Mann-Whitney rank-sum test or 
exact Fisher two-tailed test, as appropriate. 
Plac = placental; HD = hypertensive disease; Mat = maternal; CH = chronic hypertension; IUGR = 
intrauterine growth restriction; gr = grams; 95%CI = 95% confidence interval. 
Table 4 
 
There were no statistically significant differences in age, ethnicity, parity and 
conception among every case and control group. There were difference in BMI, 
gestational age at delivery and infant birth-weight. Effectively, BMI at the enrolment 
was significant higher in women with CH and maternal HD (p<0.01), placental HD 
(p<0.05).  
There were a significant lower gestational age at delivery and a lower birth-weight in 
women with placental and maternal HD, IUGR fetuses (p<0.01).  
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Variable Unaffected (n=3284) 
Early-
HD 
(n=11) 
Late-HD 
(n=111) 
CH 
(n=10) 
IUGR 
(n=56) 
Age, y, mean 
(95%CI) 
32.6 
(32.4-32.7) 
33.5 
(31.4-
35.6) 
32.9  
(32.1-33.8) 
34.8  
(31.3-38.4) 
31.7  
 (30.5-
33.0) 
BMI, Kg/m2, 
mean 
(95%CI)  
22.3 
(22.2-22.4)  
24.7 
(22.3-
27.0)  
24.6 
(23.7-25.5)  
30.4** 
(26.1-34.8) 
21.6  
(20.8-22.5)  
Ethnicity: 
Caucasian, 
% 
96.0 100.0  94.6 100.0  94.6 
Nulliparous, 
%  60.6  77.8  69.2  70.0  63.6 
Conception 
spontaneous, 
% 
 97.0  100.0  92.3  80.0  100.0 
Gestational 
age at 
delivery, 
weeks 
(95%CI) 
39.5  
(39.5-39.6) 
30.0** 
(28.4-
31.6) 
38.7** 
(38.4-39.1) 
39.6 
(38.7-40.5) 
38.7** 
(38.2-39.1) 
Infant birth 
weight, gr, 
mean 
(95%CI) 
3351 
(3335-3367) 
1158** 
(864-
1452) 
3079** 
(2967-
3191) 
3359 
(3094-3623) 
2487** 
(2397-
2576) 
* for p<0.05; ** for p<0.01: comparison with group of unaffected with Mann-Whitney rank-sum 
test or exact Fisher two-tailed test, as appropriate. 
Plac = placental; HD = hypertensive disease; Mat = maternal; CH = chronic hypertension; IUGR = 
intrauterine growth restriction; gr = grams; 95%CI = 95% confidence interval. 
           Table 5 
 
Using the second classification with standard definition of HD (early- and late-) BMI 
at the enrolment was significant higher only in women with CH (p<0.01). There was a 
significant lower gestational age at delivery and a lower birth-weight in women with 
early and late HD and IUGR fetuses (p<0.01) (table 5).  
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Placental parameters: Doppler velocimetry of the uterine arteries and biochemical 
markers in placental and maternal hypertensive disease. 
The results of Doppler examination of the uterine arteries and serum markers analysis 
are represented in Table 6. 	  
Variable Unaffected (n=3284) 
Plac HD 
(n=16) 
Mat HD 
(n=106) 
CH 
(n=10) 
IUGR 
(n=56) 
Mean UtA 
PI 
Log10 
(95%CI) 
1.60 
(1.58-1.61) 
2.36** 
(2.10-
2.62) 
1.68 
(1.57-1.78) 
1.54 
(1.18-1.89) 
1.79** 
(1.64-
1.94) 
PAPP-A 
MoM 
(95%CI) 
1.08 
(1.06-1.11) 
0.88 
(0.67-
1.09) 
0.93** 
(0.79-1.08) 
0.71* 
(0.55-0.87) 
0.92** 
(0.70-
1.13) 
BhCGMoM 
(95%CI) 
1.13 
(1.11-1.16) 
1.15 
(0.73-
1.57) 
1.13 
(0.96-1.30) 
1.06 
(0.52-1.61) 
0.95 
(0.80-
1.10) 
* for p<0.05; ** for p<0.01: comparison with group of unaffected with Mann-Whitney rank-sum 
test. 
          Table 6 
The mean uterine artery PI was significantly higher in placental HD and in IUGR 
group (p<0.01) when compared with the unaffected group (table 6, figure 1). PAPP-A 
was significant lower in maternal HD and IUGR group (p< 0.01) and in CH group 
(p<0.05). There was no significant difference in B-hCG levels through study group. 
 
Figure 1 
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Placental parameters: Doppler velocimetry of the uterine arteries and biochemical 
markers in early and late hypertensive disease. 
If we consider the early-late group, the mean uterine artery PI was significantly higher 
in early HD group and IUGR group (p< 0.01) respect control group and in late HD 
group (p< 0.05) (Table 7, figure 2). PAPP-A was significant lower in late-HD and 
IUGR group (p< 0.01) and in CH group (p<0.05). No significant differences between 
groups for B-hCG. 
 
Variable Unaffected (n=3284) 
Early-
HD 
(n=11) 
Late-HD 
(n=111) 
CH 
(n=10) 
IUGR 
(n=56) 
Mean 
UtA PI 
Log10 
(95%CI) 
1.60 
(1.58-1.61) 
2.30** 
(2.00-
2.60) 
1.71* 
(1.61-1.82) 
1.54 
(1.18-1.89) 
1.79** 
(1.64-1.94) 
PAPP-A 
MoM 
(95%CI) 
1.08 
(1.06-1.11) 
0.79 
(0.62-
0.96) 
0.94** 
(0.80-1.08) 
0.71* 
(0.55-0.87) 
0.92** 
(0.70-1.13) 
BhCG 
MoM 
(95%CI) 
1.13 
(1.11-1.16) 
1.00 
(0.75-
1.26) 
1.15 
(0.98-1.32) 
1.06 
(0.52-1.61) 
0.95 
(0.80-1.10) 
* for p<0.05; ** for p<0.01: comparison with group of unaffected with Mann-Whitney rank-sum 
test. 
          Table 7 
         
 
          Figure 2 
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Placental-maternal model: comparing each group with the other.  
The results of regression logistic analysis of every group of placental-maternal model 
with the other, are represented in table 8. 
 
 Placental HD Maternal HD 
 OR (95% CI) P OR (95% CI) P 
PI uterine 
arteries 
mean 
11.7 (4.56-30) < 0.001 1.26 (0.85-
1.86) 
0.24 
Age 0.94 (0.84-
1.05) 
0.26 1.02 (0.98-
1.07) 
0.3 
BMI 1.12 (1.01-
1.26) 
0.03 1.13 (1.09-
1.18) 
< 0.001 
Gestational 
age 
1.04 (0.37-
2.95) 
0.93 0.90 (0.61-
1.32) 
0.61 
Table 8 
 
We calculated the area under the ROC curve (AUC) for placental and maternal HD.  
Comparing placental HD with all other groups, area under the curve was 0.879 (Figure 
3). 
 
 
 
 
 
Figure 3 
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Comparing maternal HD with all other group, area under the curve was 0.666 (figure 
4). 
 
Figure 4 
 
Early and late model: comparing each group with the other.  
The results of regression logistic analysis of every group of early-late model with the 
other, are represented in table 9. 
 
 
 early HD late HD 
 OR (95% CI) P OR (95% CI) P 
PI uterine 
arteries 
mean 
7.64 (2.49-
23.40) 
< 0.001 1.49 (1.02-
2.16) 
0.04 
Age 1.02 (0.89-
1.17) 
0.76 1.01 (0.96-
1.05) 
0.61 
BMI 1.14 (1.00-
1.30) 
0.04 1.13 (1.09-
1.17) 
<0.001 
Gestational 
age 
0.56 (0.14-
2.17) 
0.40 0.95 (0.65-
1.39) 
0.81 
Table 9 
 
Comparing early HD with all other groups, area under the curve for was 0.858 (figure 
5). 
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Figure 5 
Comparing late HD with all other groups, area under the curve for was 0.668 (figure 
6). 
 
Figure 6 	  
Table 10 shows the performance of first trimester screening with the two 
classifications (5% and 10% false positive rate). 
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 5% false positive 10% false positive 
 sensitivity LR+ LR- sensitivity LR + LR - 
Placental 
HD 
44% 10.65 0.59 50% 5.55 0.55 
Maternal 
HD 
16% 3.20 0.88 28% 3.10 0.79 
Early HD 33% 8.23 0.69 44% 4,76 0.61 
Late HD 13% 3.20 0.90 25% 2.59 0.81 
Table 10 
Placental versus Maternal hypertensive disorders 
Comparing placental HD with maternal HD, mean uterine arteries PI was significantly 
higher in hypertensive disorders of placental origin with OR of 12.84 (p = <0.001, 
Table 11). 
 
 OR (95% 
CI) 
P 
PI uterine 
arteries 
mean 
12.84 (3.27-
50.38) 
< 0.001 
Age 0.89 (0.77-
1.04) 
0.14 
BMI 1.04 (0.90-
1.23) 
0.54 
Gestational 
age 
1.35 (0.38-
4.80) 
0.64 
Table 11 
Comparing placental with maternal HD, area under the curve was 0.844 (figure 7). 
 Figure	  7	  
Comparing early and late HD, there was not the same result (table 12).  
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 OR (95% CI) P 
PI uterine 
arteries 
mean 
5.50 (1.44-
20.91) 
0.01 
Age 1.03 (0.86-
1.22) 
0.77 
BMI 1.07 (0.90-
1.29) 
0.48 
Gestational 
age 
0.62 (0.14-
2.64) 
0.51 Table	  12	  
 
 
The area under the curve (AUC) was 0.775 (figure 8). 
 
	  	   Figure	  8	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IUGR and CH: comparing each group with all the population.  
 
The results of regression logistic analysis of IUGR and CH group with the other 
population are represented in table 13. 
 IUGR CH 
 OR (95% CI) P OR (95% CI) P 
PI uterine 
arteries 
mean 
1.95 (1.18-
3.25) 
0.01 1.04 (0.30-
3.57) 
0.95 
Age 0.96 (0.90-
1.01) 
0.14 1.11 (0.96-
1.29) 
0.16 
BMI 0.94 (0.86-
1.01) 
0.16 1.30 (1.18-
1.43) 
<0.001 
Gestational 
age 
0.84 (0.49-
1.44) 
0.53 0.67 (0.20-
2.29) 
0.52 
Table 13 
 
Comparing IUGR with all other groups, area under the curve for was 0.626 (figure 9). 
 
Figure 9 
 
Comparing CH with all other groups, area under the curve for was 0.833 (figure 10). 
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Figure 10 
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Discussion 
 
The aim of our study is to validate a new classification of gestational hypertensive 
disorders recently proposed in the scientific community.  
Gestational hypertensive disorders is commonly classified according to gravity (mild, 
moderate, severe) or according to gestational age at insurgence (or at delivery). 
Nevertheless, the clinical and physiopathological features of the disease are not 
included in this type of classification. It is commonly believed that there exist two types 
of hypertensive disorders, originating by different physiopathological conditions. 
Disorders of placental origin, where gestational hypertension or preeclampsia are 
associated to IUGR, and maternal hypertension diseases, where the fetal growth appears 
within normal ranges, independently of gestational age at the diagnosis. Placental and 
maternal hypertensive diseases recognize different aetiologies and, therefore, develop 
through different models of maternal cardiovascular adaptation in the latent phase of the 
disease.  
Scientific papers in recent years have recognized in the early-late classification a 
different physiopathological expression of the disease, assigning the early one to a 
placental defect, and thus leading more often to problems concerning the fetal growth. 
Late preeclampsia, instead, is more correlated to maternal problems. We think that a 
classification only based on time is not enough: placental preeclampsia appears quite 
often at an early stage, but it is not unusual at later times with IUGR fetuses as well. In 
our series 9 placental diseases developed before 34 weeks and 7 after 34 weeks.  
The analysis of uterine arteries in first trimester has been used in many studies as a 
predictive marker for placental pathologies: this kind of analysis was previously limited 
to second and third trimester only. Since the placental development is not completed at 
an early stage (first trimester), it is very important to identify risk factors at this age that 
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could lead to a placental pathology, in order to plan a series of preventive strategies 
(drugs, diet, behaviour). 
Accurate prediction of gestational hypertensive disorders and intrauterine growth 
restriction is crucial to allow judicious allocation of resources for monitoring and the 
development of preventive treatment to improve maternal and perinatal outcomes. Early 
identification of women at risk of gestational hypertension diseases facilitates targeted 
surveillance and intervention 88 . There are likely to be significant advantages in 
predicting hypertensive diseases during the first trimester, as opposed to the second; 
since the disease process is already established by the mid second trimester, any 
successful preventative measure will need to be instituted in pregnancy as early as 
possible.  
 
Uterine arteries 
In our study, we investigated uterine arteries during the first trimester in healthy women 
that have later developed hypertensive disease. We choose to analyse the interval 
between the 11th and 13th week of gestation because in this period women use to make 
the combined sonographic and biochemical testing for chromosomal and other major 
defects. We used the two classifications of hypertensive disorders: the time-based 
definition (early: before 34 weeks, late: after 34 weeks) and the physiopathological-
based (placental is associated to IUGR, and maternal when the fetal growth appears 
within normal ranges). 
In our work IUGR assessment was based on biometric prenatal evaluation and not on 
the birth weight of the fetus. This led us to consider only those small fetuses recognized 
during pregnancy, and not considering as IUGR fetuses small at birth and not diagnosed 
prenatally.  
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We observe that a different choice of criteria affect the predictive power of uterine 
arteries. Mean uterine arteries PI was significantly higher, both in case of placental and 
early hypertensive diseases, while no differences were observed between maternal and 
late hypertensive diseases compared to controls. The difference was even more evident 
using the new etiologic classification. 
Concerning prediction of the logistic regression, the validity of the uterine arteries 
Doppler velocimetry has been confirmed for early identification of women at risk of 
developing a hypertensive disease, especially of placental origin. In effect the area 
under the ROC curve for placental hypertensive diseases was 0.879, whereas for early 
diseases was 0.858.  
Instead, uterine artery Doppler velocimetry in maternal and late hypertensive diseases 
was comparable to that of the general population. These data confirm the hypothesis of 
existence of two different hypertensive disorders characterized by different aetiology 
and clinic, but not recognized only by temporal criteria. In fact, Doppler-velocimetry 
study was more effective in identification of hypertensive disorders especially of 
placental origin, as well as the early ones.  
The literature suggests that early preeclampsia/IUGR is associated with defective 
invasion of the spiral arteries, whereas the spiral artery defect plays a much smaller role 
in the cases closer to term89. Thus, term preeclampsia/IUGR seems to be associated with 
normal trophoblast transformation in the first trimester, and late atherosclerotic changes 
in spiral arterioles. Such late changes may be the consequence of increased placental 
mass, as occurs in diabetic and twin pregnancies, related to the senescence of the 
placenta in prolonged pregnancy or as a result of placental edema and necrosis in fetal 
hydrops90.  
Abnormal uterine artery Doppler studies in the first trimester have been shown to be 
associated with preeclampsia/IUGR. Gomez et al. reported that the sequence of changes 
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in uterine artery Doppler between the first (11 and 14 weeks) and second (20 and 24 
weeks) trimesters correlates with the subsequent development of preeclampsia and 
IUGR91.  
The detection rate of uterine artery screening for preeclampsia at any gestation is better 
for severe than for mild disease. Increased resistance indices in the first trimester are 
particularly effective in identifying preterm, rather than term, preeclampsia92 93 94. 
In addition, uterine artery Doppler in the first and the second trimesters was shown to 
have a remarkably higher sensitivity in women with preeclampsia complicated by 
small-for-gestational-age (SGA) babies compared with uncomplicated preeclampsia or 
SGA alone95. 
Our study are in agreement with the literature data and shows that the mean uterine 
artery PI was significantly higher in women who subsequently developed placental 
hypertensive diseases, but not in maternal hypertensive disorders, confirming indirectly 
our hypothesis that maternal form is not associated with impaired placentation. 
In the last 10-15 years hypertensive disorders classification in early and late, based at 
the time of onset before or after 34 weeks of gestation, was the most commonly used 
classification. The classification based exclusively on a temporal criteria has not been 
sufficient to assess these diseases. Nevertheless, all screening tests developed until now 
based on this temporal classification: maybe this is why that they proved inadequate. 
Moreover in our study the physiopathological-based classification allowed us to identify 
5 additional cases respect to the early-late classification (placental HD n= 16. Early HD 
n=11). This is very important for clinical application. Placental form represents a 
disease able to compromise the pregnancy on various fronts (maternal and fetal) making 
the picture much more complex.  
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Uterine arteries Doppler in first trimester didn’t show significant correlation with IUGR 
e CH group according to the literature: for IUGR, the sensitivity of uterine arteries 
Doppler in the first trimester was 15%71. 
 
PAPP-A 
PAPP-A is an insulin-like growth factor binding protein (IGFBP) protease with 
specificity for IGFBP 2 and 4. Reduced levels of PAPP-A may result in increased 
amounts of insulin-like growth factor (IGF) being bound to its carrier proteins and 
hence not available at the cell receptor level to stimulate fetal growth and trophoblast 
invasion of the decidua96. Many studies have reported reduced maternal serum PAPP-A 
concentration at 11–14 weeks and increased risk for subsequent development of 
preeclampsia, IUGR and preterm delivery 97 98 99.  
For IUGR, the sensitivity of PAPP-A below 5 th percentile in the first trimester were 8–
33% 99. 
Our data show that MoM PAPP-A was significantly lower in maternal form, late onset 
hypertensive diseases and IUGR group. 
We think there is an association with metabolic syndrome: Sifakis et al 100  has 
demonstrated that at 11–13 weeks’ gestation in pregnancies destined to develop 
preeclampsia compared with unaffected controls, the median maternal serum IGFBP-3 
and uterine artery PI were higher and serum PAPP-A was lower. Evidence from both in 
vitro and in vivo studies suggested that increased levels of IGFBP-3 are associated with 
hyperglycemia, metabolic syndrome and increased insulin resistance101. 
In women destined to develop late hypertensive disorders, placental perfusion and fetal 
growth are often normal and the main pathophysiological processes resemble those of 
the metabolic syndrome with an increase in adipose tissue, impaired glucose tolerance 
and increased insulin resistance102 103. In non-pregnant women, insulin is the main 
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regulator of IGFBP-1, and studies in pregnancy reported that IGFBP-1 production by 
the decidualized stroma is inhibited by insulin104. Always in 2011, Sifakis et al105 wrote 
that the low levels of IGFBP-1 in women destined to develop preeclampsia may be the 
consequence of the associated hyperinsulinemia and increased insulin resistance106. 
 
Maternal factors 
Among the maternal factors that may contribute to the development of maternal 
hypertensive disorders, body mass index seems to play an important role. In our study 
maternal form showed a higher values of BMI than placental ones. This factor is well 
related to metabolic syndrome, low grade chronic inflammation and insulin resistance 
and it may be correlated with the physiopathology of the disease. Fat tissue is 
metabolically active, producing numerous inflammatory mediators (leptin, adiponectin, 
interleukins (IL)-1, IL-6, IL-8, IL-10, tumor necrosis factor (TNF), interferon-a and 
monocyte chemoattractant protein (MCP)-1. Adipokines are secreted into the systemic 
circulation and represent a trigger point to activate the inflammation cascade. All this 
process that is fundamental in maternal hypertensive disorders, could influence also 
placental form, worsening and enhancing the inflammation process typical of 
hypertensive disease.  
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Conclusion 
 
Considering the seriousness of placental form and its impact on the fetus, the use of a 
classification allowing to recognize different manifestations of the disease could be the 
first step towards a reliable preventive practice. The classical temporal definition of 
hypertensive disease may underestimate the risk, leading to a failure of screening and 
prevention. This change of classification, not based on gestational age anymore but on 
the aetiology of the disease, allows us to carefully evaluate the risk of fetal distress and 
additional problems. The most important goal is to identify placental hypertensive 
disorders that are associated with the highest perinatal and maternal morbidity and 
mortality.  
This model is a potentially helpful tool to identify the highest risk group of patients that 
may develop important complications. Even more, the possibility of giving a prediction 
rate with good specificity in one step could be important in some health situations 
where the follow-up of the patients could be difficult. 
The ability to predict in very early pregnancy those women at risk for PE might 
decrease maternal and fetal morbidity through closer surveillance by physicians 
experienced or specialized in high-risk obstetrics, as well as delivery at tertiary care 
centres107. Centralized care of pregnancies at high risk for hypertensive disorders would 
also lead to a more effective concentration of research activity in an attempt to improve 
the understanding of the pathophysiology and treatment of the condition. 
In conclusion, the screening test proposed with the new aetiological classification, 
seems to be very effective in prediction of placental hypertensive disorders, and in 
discrimination in maternal hypertensive disorders.  
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We have demonstrated that, classifying hypertensive disorders according to aetiological 
criteria, the predictive power increases, allowing to identify a larger number of pregnant 
women at risk of developing a hypertensive disorder.  
Early identification of women at risk is very important, especially in cases of placental 
form, because this disease is responsible for serious maternal and fetal consequences. 
The prevention is a fundamental resource, and screening for this pathology would 
change the history of the disease.  
Many studies are still needed, both to understand the aetiology of these diseases and for 
identifying a cure, but our work could improve clinical management of these patients. 
 
Limits of the study 
We acknowledge that the number of cases in the study is too small (the prevalence of 
HD in our cohort is low) to draw firm conclusions, and confirmation from larger studies 
will be required. Smoking habit was not considered. Diagnosis of early and late 
preeclampsia is based on time at delivery and not at time of diagnosis.  
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